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Abstract
Patients with head-and-neck cancer can develop both lung meta-
stasis and primary lung cancer during the course of their disease.
Despite the clinical importance of discrimination, reliable diagnos-
tic biomarkers are still lacking. Here, we have characterised a
cohort of squamous cell lung (SQCLC) and head-and-neck (HNSCC)
carcinomas by quantitative proteomics. In a training cohort, we
quantified 4,957 proteins in 44 SQCLC and 30 HNSCC tumours. A
total of 518 proteins were found to be differentially expressed
between SQCLC and HNSCC, and some of these were identified as
genetic dependencies in either of the two tumour types. Using
supervised machine learning, we inferred a proteomic signature
for the classification of squamous cell carcinomas as either
SQCLC or HNSCC, with diagnostic accuracies of 90.5% and 86.8%
in cross- and independent validations, respectively. Furthermore,
application of this signature to a cohort of pulmonary squamous
cell carcinomas of unknown origin leads to a significant prog-
nostic separation. This study not only provides a diagnostic
proteomic signature for classification of secondary lung tumours
in HNSCC patients, but also represents a proteomic resource for
HNSCC and SQCLC.
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Introduction
Head-and-neck squamous cell carcinoma (HNSCC) affects more
than 500,000 patients every year worldwide (Ferlay et al, 2010;
Jemal et al, 2011; Chaturvedi et al, 2013). Besides local recur-
rences, long-term survival of patients with resectable HNSCC is
limited by frequently occurring distant metastases, of which up
to 80% occur in the lung (Calhoun et al, 1994; Jones et al,
1995; de Bree et al, 2000; Ferlito et al, 2001; Liao et al, 2007).
Thus, patients with HNSCC are screened for lung metastasis
after tumour resection (de Bree et al, 2000; Merkx et al, 2002).
However, because tobacco-smoking is not only a major risk
factor for the development of HNSCC, but also for lung cancer,
HNSCC patients are furthermore at high risk of developing
metachronous squamous cell carcinomas of the lung (SQCLC;
Talamini et al, 2002). Differentiation between lung metastasis
of HNSCC (metHNSCC) and SQCLC is of clinical importance,
as the diagnosis guides the therapeutic procedures that can
range from curative treatment for SQCLC patients to palliative
treatment for patients with metastatic HNSCC (Atabek et al,
1987; Jacobs et al, 1992; Jones et al, 1995; Kuriakose et al,
2002; Henschke et al, 2003; Battafarano et al, 2004; Wisnivesky
et al, 2004; Pignon et al, 2008; Shiono et al, 2009). Despite this
clinical importance, reliable biomarkers for differentiation
between SQCLC and HNSCC metastasis in the lung are
currently lacking; this may be due, at least partly, to the over-
lapping aetiology, morphology and biology of these tumour
entities. Because decision-making by clinicians currently relies
on non-validated clinical and imaging criteria, there is an
urgent need for reliable molecular biomarkers that can differen-
tiate between SQCLC and HNSCC lung metastases (Geurts et al,
2005).
Head-and-neck squamous cell carcinoma and SQCLC have
been extensively studied at the genomic and transcriptomic
levels. However, in addition to their shared morphology,
HNSCC and SQCLC exhibit largely overlapping patterns of
genetic mutations and copy number alterations (van Oijen
et al, 2000; Tabor et al, 2002; Geurts et al, 2005, 2009; Talbot
et al, 2005; Vachani et al, 2007; Cancer Genome Atlas
Research, 2012; Cancer Genome Atlas, 2015; Ichinose et al,
2016a). Given the apparent inability of genomic features to dif-
ferentiate reliably between HNSCC and SQCLC, we have inves-
tigated a clinically and genetically well-characterised cohort of
SQCLC, HNSCC and undetermined lung tumours by quantita-
tive mass spectrometry-based proteomics. We reasoned that
this proteomic approach, rather than genomic and transcrip-
tomic studies, may identify a suitable biomarker panel and
may also provide some more general insights into the biology
of these tumours.
Results
Comparative proteomic characterisation of squamous cell
carcinomas of the lung and the head-and-neck region
Differentiation between metHNSCC and primary SQCLC is of funda-
mental clinical importance for therapeutic stratification. However,
diagnostic biomarkers are so far lacking, owing to the large number
of morphological and genomic features that are shared by these
tumour entities.
Because the two tumour types have not been systematically
compared at the proteome level, we wished to explore the possibil-
ity of identifying proteomic diagnostic biomarkers. To this end, we
characterised the protein expression profiles of 44 formalin-fixed
and paraffin-embedded (FFPE) SQCLC tissues and 30 FFPE HNSCC
tissues from patients who developed squamous cell tumours in the
lung in the course of their disease. All SQCLCs in our cohort were in
tumour stage I–III with grades 2–3, and the tumour stage of HNSCCs
ranged from I to IV with grades 2–3 (see Table 1 and Dataset EV1
for detailed patient characteristics). All patients were treated by
surgery and 40 of them had received additional adjuvant (chemo)ra-
diotherapy. None of the patients had received neoadjuvant therapy
or primary chemoradiotherapy. Squamous cell histology of all
samples was confirmed by expert pathology review including
immunohistochemical staining of the markers p63 and cytokeratin
5/6 (Fig 1A). Moreover, targeted next-generation sequencing
revealed similar mutation patterns in both HNSCC and SQCLC
samples from our cohort (Fig 1B). This is in accordance with
genomic studies that have reported similar somatic mutation
patterns and frequencies in both diseases, as illustrated in Fig 1C
(Cancer Genome Atlas Research N, 2012; Cancer Genome Atlas,
2015). The mutations detected affected mostly the PI3-kinase (PI3K)
and Ras pathways, receptor tyrosine kinases (RTK), TP53 and the
NFE2L2/KEAP1 pathway (Fig 1B and Dataset EV1). Notably, three
HNSCC samples were positive for human papillomavirus (HPV) 16.
For the proteomic characterisation of the 74 tumour samples (44
SQCLC, 30 HNSCC), we combined a filter-aided sample preparation
approach (FASP) with Super-SILAC-based quantitative mass spec-
trometry (Fig 2A; Wisniewski et al, 2009; Erde et al, 2014; Bohnen-
berger et al, 2015). Before protein extraction, tumour cell areas
were marked under microscopic view by expert pathologists, and
the tumour cell content was enriched to >80% by macrodissection,
which is a well-established technique for the molecular analysis of
tumour tissue samples in routine pathology diagnostics (Cree et al,
2014). After FASP-based protein extraction, the tumour-derived
proteins were mixed in equimolar amounts with a Super-SILAC
spike-in protein standard that was used for relative quantification of
protein abundance. The Super-SILAC standard consisted of the four
lung cancer cell lines NCI-H2228, HCC15, HCC44 and NCI-H1339. It
represented adequately the proteomes of SQCLC and HNSCC
samples, as reflected by the fact that more than 90% of the SILAC
ratios were within a fivefold range, allowing accurate and compara-
ble protein quantification (Fig 2B). The protein mixture was
digested with the protease trypsin, and the resulting peptides were
finally analysed by high-resolution mass spectrometry.
We quantified a total of 6214 proteins in SQCLC and HNSCC
samples (Datasets EV2 and EV6), thus providing the largest
proteome resource for squamous cell carcinomas to date. On
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average, we quantified 2,251 (range 1,317–3,314) proteins in a total
of two replicates of each of the tissue samples analysed (Fig 2C).
Notably, the correlation coefficients for the individual replicates
ranged from 0.802 to 0.975 (0.949  0.0266; Fig EV1A), and the MS
signal intensities spanned six orders of magnitude, which reflects
the identification and quantification of proteins with high and those
with low abundance (Fig 2D). Moreover, the results obtained on dif-
ferent mass spectrometry platforms were comparable and repro-
ducible, as revealed by a direct comparison of the protein
expression profiles of six randomly selected tumour samples that
were analysed on both an Orbitrap Fusion and a Q Exactive HF
mass spectrometer (both Thermo Fisher; Fig EV1B and C).
As a first exploratory analysis, we performed a principal compo-
nent analysis on the full proteomic data. This revealed significant
proteomic differences between HNSCC and SQCLC, as it separated
the two tumour types into two partially overlapping groups
reflecting the cell of origin of the respective squamous cell carcino-
mas (Fig 2E).
Quantitative proteomics reveals differences in protein
expression between SQCLC and HNSCC
In our proteomic dataset, we identified 518 proteins with signifi-
cantly different expression levels in HNSCC and SQCLC by univariate
data analysis using an empirical Bayes method with a linear regres-
sion model (Figs 3A and EV2A, and EV3A, Dataset EV3). In line with
previously published gene expression and immunohistochemistry
data, cytokeratin 19 (CK19) was among the most strongly up-regu-
lated proteins in our SQCLC cohort (Ichinose et al, 2016a; Figs 3A
and EV2B). Interestingly, previously described oncogenic factors—
such as HMG-CoA synthase 1 (HMGCS-1) and FAM83H—were also
found to be differentially expressed in SQCLC and HNSCC. These
proteins have been described as being overexpressed and relevant
for tumour cell survival in various cancer entities (Snijders et al,
2017; Zhao et al, 2017). To systematically investigate the functional
relevance of the proteins that were found to be differentially
expressed in SQCLC and HNSCC, we have integrated our proteomic
Table 1. Patient characteristics training cohort.
Characteristic
Squamous cell lung
carcinoma (n = 44)
Squamous cell head-and-neck
carcinoma (n = 30)
Age median (range) [years] 66 (49–81) 55 (31–76)
Male sex [no. (%)] 32 (72.7) 26 (86.7)
Smoking or tobacco use [no. (%)]
Current or former 22 (50.0) 28 (93.3)
Never 0 (0.0) 2 (6.7)
Not reported 22 (50.0) 0 (0.0)
Site of primary tumour [no. (%)]
Lung 44 (100.0) —
Larynx — 12 (40.0)
Oral cavity — 5 (16.7)
Pharynx — 13 (43.4)
Systemic therapy regimen [no. (%)]
Adjuvant therapy 22 (50.0) 18 (60.0)
Neoadjuvant therapy 0 (0.0) 0 (0.0)
Overall survival: median follow-up time
(range) [months]
19 (1–38) 57 (7–169)
No. of reported deaths (%) 17 (31.8) 20 (66.7)
Local relapse of HNSCC [no. (%)] — 5 (16.7)
Time HNSCC until lung tumour:
Median (range) [months]
— 20 (1–121)
Staging UICC (7th edition)
Stage I [no. (%)] 14 (31.8) 1 (3.3)
Stage II [no. (%)] 11 (25.0) 5 (16.7)
Stage III [no. (%)] 19 (43.2) 7 (23.3)
Stage IV [no. (%)] 0 (0.0) 17 (56.7)
TP53 sequence
Wild type [no. (%)] 12 (27.3) 12 (40.0)
Mutated [no. (%)] 31 (70.5) 12 (40.0)
Unknown 1 (2.2) 6 (20.0)
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results with recently published functional genomic data from genome-
scale CRISPR/Cas9-based loss-of-function screens (Doench et al, 2016;
Meyers et al, 2017; https://figshare.com/articles/Broad_Institute_
Cancer_Dependency_Map_CRISPR_Avana_dataset_18Q1_Avana_
public_18Q1_/5863776). To this end, we have investigated if any of
the 518 differentially expressed proteins were identified as genetic
dependencies (i.e. regulators of proliferation and/or cell survival) in 12
HNSCC and 10 SQCLC cell lines (for details, see Dataset EV3). Interest-
ingly, this analysis revealed that a subset of the differentially expressed
genes/proteins shows preferential genetic dependencies in either
HNSCC or SQCLC (Fig 3B, Dataset EV3). For instance, the mitotic
checkpoint protein BUB3 and dolichol-phosphate mannosyltransferase
subunit (DPM1) were stronger dependencies in HNSCC, while the
adenylosuccinate lyase (ADSL), the cytochrome b-c1 complex subunit
1 (UQCRC1) and the NADH dehydrogenase 1 beta subcomplex subunit
4 (NDUFB4) belonged to a subset of proteins that reflected stronger
dependencies in SQCLC. Notably, a genetic dependency on some of
the most differentially expressed proteins was observed (Fig EV3B).
This result highlights the tumour-type-specific functional relevance
of a subset of the differentially expressed marker proteins.
Next, we validated our proteomic data by performing immuno-
histochemical staining for CK19, HMGCS-1, FAM38H, LGALS7 and
ferritin light chain (FTL) in 212 SQCLC and 343 HNSCC tissues
(Table 2 and Dataset EV4), which confirmed our proteomic data in
that CK19, HMGCS-1 and FTL were more strongly expressed in
SQCLC, as opposed to LGALS7 and FAM83H, both of which showed
stronger expression in HNSCC (Figs 3C and D, and EV2B). To
exclude the possibility that the observed differential expression of
FTL was caused by differences in microvessel densities between
SQCLC and HNSCC, we performed CD34 staining, which confirmed
similar microvessel densities in the two tumour types (Fig EV2C).
Notably, no differences in expression of proteins related to the most
recurrently mutated pathways shown in Fig 1B and C were
observed between SQCLC and HNSCC (Fig EV2D).
On the basis of the described results, we performed a gene-
set-enrichment analysis of the 518 differentially expressed proteins
to gain insight into pathways whose regulation differs between
SQCLC and HNSCC. This revealed that (i) vesicle transport,
(ii) glycosylation and (iii) RNA-processing including splicing (each
adjusted P value was < 0.001) were among the most differen-
tially regulated pathways in SQCLC and HNSCC (Fig 3E). Our
proteomic data suggest that these processes are regulated differen-
tially in SQCLC and HNSCC cells and might contribute to their
pathophysiology.
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Figure 1. Genetic comparison of lung and head-and-neck carcinomas.
A Representative H&E and immunohistochemical stainings of CK5/6 and p63 in pulmonary and head-and-neck squamous cell carcinomas. Scale bar: 500 lm.
B Heatmap showing somatic mutations in defined pathways and HPV status for all HNSCC and SQCLC cases analysed. (Blue, no mutation/no HPV detected; red,
mutation/HPV detected; white, no data available)
C Comparison of mutation rates in HNSCC (n = 279) and SQCLC (n = 178) cases from TCGA. Genes exhibiting a mutation rate > 0.25 in both cancer types are labelled.
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Figure 2. Proteomic comparison of lung and head-and-neck carcinomas.
A Schematic experimental workflow: Patient-derived tumour samples were lysed according to the FASP protocol; the resulting proteins were mixed in equimolar
amounts with a Super-SILAC spike-in standard and digested with trypsin. The MS analysis of each sample was performed in duplicate, and data analysis was
performed with the software packages MaxQuant, Perseus and R.
B Representative histogram showing the SILAC ratio distribution between the Super-SILAC standard and SQCLC (left) and HNSCC (right) samples.
C Boxplot showing the numbers of quantified proteins, derived from 44 SQCLC and 30 HNSCC tissue samples. The central line in the boxes represents the median
number of proteins over all samples, and upper and lower borders of boxes correspond to 25% and 75% quantiles. Whiskers indicate minimum and maximum.
D Distribution of MS-based protein signal intensities in all 74 tissue samples of the training cohort.
E Principal component analysis of SQCLC (n = 44; blue) and HNSCC (n = 30; red) protein expression. Shown are the first two principal components, accounting for
8.51% and 8.03% of the total variance in the data, respectively.
ª 2018 The Authors EMBO Molecular Medicine 10: e8428 | 2018 5 of 15
Hanibal Bohnenberger et al Proteomic map of squamous cell carcinomas EMBO Molecular Medicine
AC
D
B
E
Figure 3.
6 of 15 EMBO Molecular Medicine 10: e8428 | 2018 ª 2018 The Authors
EMBO Molecular Medicine Proteomic map of squamous cell carcinomas Hanibal Bohnenberger et al
A diagnostic proteomic signature for differentiation between
primary SQCLC and head-and-neck cancer metastasis in the lung
As we were aiming to obtain a robust diagnostic signature with high
classification accuracy, we next trained a linear support vector
machine (SVM) to discriminate between SQCLC and HNSCC
(Fig 4A). Training was performed using a bootstrapping procedure to
assess robustness of predictions and guard against overfitting. Using
the full set of proteins as features in a crossvalidation approach, the
predictor achieved a bootstrapped accuracy of 90.5  0.05, a sensi-
tivity of 85.7% and a specificity of 93.7%. For comparison, we used
four other classification algorithms, which achieved comparable
performance (Fig 4B). We then assessed the extent to which reducing
the size of the signature set would affect classification performance.
Using recursive feature elimination, we were able to reduce the set to
about 1,100 proteins without affecting classification performance.
Thereafter, the accuracy of the classification began to decline gradu-
ally, with a bootstrapped accuracy of 76.8% using 100 proteins, 65%
using the top 25 proteins and only 57.2% using a single protein for
classification (Fig 4C). This indicates clearly that reliable distinction
◀ Figure 3. Validation of proteomic differences of lung and head-and-neck carcinomas.A Volcano plot relating adjusted p values for differential protein expression to averaged normalised SILAC ratios of two replicates. Red (higher expression in HNSCC)
and blue (higher expression in SQCLC) dots indicate significantly regulated proteins (P < 0.05).
B Two-class comparison of genetic dependencies from a publically available genome-scale CRISPR-Cas9 screen of HNSCC (12 cell line) versus SQCLC (10 cell lines)
identified a subset of differentially expressed proteins that were also differential dependencies in these tumour types. The x-axis represents the effect size of the
mean difference of dependency scores in HNSCC compared to SQCLC cell lines. Positive effect size indicates a greater mean dependency in HNSCC; negative effect
size indicates a greater mean dependency in SQCLC. The y-axis represents the statistical significance of differential enrichment calculated as -log10(P-value) from a
two-sided t-test. The P-values used for this plot are uncorrected for multiple hypothesis testing. Highlighted in green are genetic dependencies that were also
identified as differentially expressed proteins in our study.
C, D Immunohistochemical analysis of the expression of HMGCS-1 (P = 0.0014), FTL (P = 0.0001) (C), LGALS7 (P = 0.0001) and FAM83H (P = 0.0001) (D) in an
independent cohort of 212 SQCLC and 343 HNSCC cases. Scale bar indicates 100 lm. Shown are mean values and standard deviation. Statistical significance was
assessed using Wilcoxon–Mann–Whitney test.
E Pathway enrichment analysis for proteins differentially expressed in HNSCC and SQCLC.
Table 2. Patient characteristics immunohistochemistry cohort.
Characteristic
Squamous cell
lung carcinoma
(n = 212)
Squamous cell
head-and-neck
carcinoma (n = 343)
Age median (range)
[years]
66 (42–83) 57 (20–88)
Male sex [no. (%)] 178 (83.9) 277 (80.8)
Site of primary tumour [no. (%)]
Lung 212 (100.0) —
Larynx — 80 (23.3)
Oral cavity — 107 (31.2)
Pharynx — 156 (45.5)
Staging UICC (7th edition)
Stage I [no. (%)] 88 (41.5) 14 (4.1)
Stage II [no. (%)] 63 (29.7) 33 (9.6)
Stage III [no. (%)] 59 (27.8) 49 (14.3)
Stage IV [no. (%)] 2 (0.9) 196 (57.1)
▸Figure 4. Diagnostic proteomic signature for HNSCC metastasis in the lung.A Schematic computational workflow: The SVM predictor was initially developed using a bootstrapping procedure on n = 44 primary SQCLC and n = 30 HNSCC cases.
An independent set of n = 38 tumours was used for validation, before we applied the classifier to n = 51 lung tumours of unknown origin. Survival analysis was used
to assess classification performance on this final dataset.
B Classification accuracy of five different machine-learning methods used for classification of HNSCC vs. SQCLC is as follows: SVM, support vector machine with a linear
kernel; RPART, classification and regression tree (CART); NB, naïve Bayes classifier; PAM, partitioning around medoids/nearest shrunken centroids; and PLR, L1-
penalised logistic regression. All models were fitted using the R/Bioconductor package “caret”. Model hyperparameters were optimised using caret’s tuning option;
accuracies were computed by bootstrapping with 25 repetitions, shown are mean accuracy  standard deviation.
C Classification accuracy using a linear support vector machine. The figure shows the bootstrapped accuracy achieved over the number of proteins included in the
computation. Feature selection was performed using recursive feature elimination.
D Boxplot showing the number of quantified proteins derived from 19 SQCLC, 19 HNSCC and 51 squamous cell lung tumours of unknown origin derived from HNSCC
patients. The central line in the boxes represents the median number of proteins over all samples, and upper and lower borders of boxes correspond to 25% and 75%
quantiles. Whiskers indicate minimum and maximum.
E Classification accuracy of the SVM prediction model described, in an independent validation cohort of 19 SQCLC and 19 HNSCC cases.
F Representative H&E and immunohistochemical stainings of CK5/6 and p63 in squamous cell lung tumours of unknown origin derived from HNSCC patients. Scale bar:
500 lm.
G Kaplan–Meier analysis of overall survival (OS) in which all patients with lung tumours were grouped according to the clinical classification (left, median survival
SQCLC: 55 months; metHNSCC: 31 months) or proteomic classification (right, median survival SQCLC: 55 months; metHNSCC: 8 months) of the tumour as metHNSCC
or SQCLC. The P value is from a log-rank test.
H Kaplan–Meier analysis of overall survival (OS) in which only the patients that were independent from the training cohort were grouped according to the clinical
classification (left, median survival SQCLC: 84 months; metHNSCC: 35 months) or proteomic classification (right, median survival SQCLC: 84 months; metHNSCC:
5 months) of the tumour as metHNSCC or SQCLC. The P value is from a log-rank test.
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between these closely related tumour types will only be possible if
complex protein expression signatures, rather than single immuno-
histochemical markers, are used.
In the next step, and as an independent validation of our diag-
nostic proteomic signature, we analysed the protein expression pro-
files of 38 independent tumour samples, of which 19 were either
confirmed primary SQCLC or primary HNSCC cases. A median of
2841 (range 2,111–3,067) proteins was quantified in each of the 38
samples (Fig 4D), and we subsequently applied our diagnostic
signature to classify the tumours as either SQCLC or HNSCC on the
basis of their protein expression profiles. Similar to the crossvalida-
tion analysis, the diagnostic accuracy in this independent validation
cohort was 86.8%, the sensitivity 85% and the specificity 88.9%
(Fig 4E).
On the basis of these results, we finally applied our proteomic
approach to classify 51 squamous cell lung tumours of undeter-
mined origin derived from patients with a history of HNSCC as
either primary SQCLC or metHNSCC. Again, squamous cell histol-
ogy of all samples was confirmed by histomorphology and immuno-
histochemical staining (Fig 4F), and targeted next-generation
sequencing revealed mutation patterns similar to those for HNSCC
and SQCLC (Fig EV4A). We quantified a median of 2787 proteins
(range 1,830–4,444) in each of the tissue samples (Fig 4D) and,
again, more than 90% of the SILAC ratios were within a fivefold
range (Fig EV4B).
It should be noted that 23 of these secondary tumours were
derived from patients whose primary HNSCC tumours were
included in the training cohort of HNSCC patients described
above. Of all the tumours analysed, 40 had been clinically classi-
fied as metHNSCC and 11 as primary lung cancer according to
criteria of a classification score that is used in clinical routine
(Fig EV4C; Ichinose et al, 2016b). This score is based on various
clinical variables, including local relapse of the HNSCC, the time
between HNSCC and the lung tumour and the number of tumour
sites in the lung (see Table 3 and Dataset EV5 for details of the
clinical samples). As a surrogate marker, a prognostic disadvan-
tage would be expected for patients with metHNSCC compared
with localised primary SQCLC. However, application of the clini-
cal classifier did not show any differences in survival (Fig 4G,
left). In contrast, when the SVM classifier was used to assign the
samples to either HNSCC or SQCLC, significant differences in
overall survival were observed between the two groups, with
median survival of 8 months in the predicted metHNSCC patients
versus a median survival of 55 months in the predicted SQCLC
Table 3. Patient characteristics validation cohorts.
Characteristic
Squamous cell lung
carcinoma (n = 19)
Squamous cell head-and-
neck carcinoma (n = 19)
Lung tumour of unknown origin
after HNSCC (n = 51)
Age median (range) [years] 64 (43–80) 58 (44–78) 63 (31–78)
Male sex [no. (%)] 16 (84.2) 18 (94.7) 43 (84.3)
Smoking or tobacco use [no. (%)]
Current or former 19 (100.0) 15 (78.9) 41 (80.4)
Never 0 (0.0) 4 (21.1) 3 (5.9)
Not reported 0 (0.0) 0 (0.0) 7 (13.7)
Site of primary tumour [no. (%)]
Lung 19 (100.0) — —
Larynx — 6 (31.6) 13 (25.5)
Oral cavity — 4 (21.1) 10 (19.6)
Pharynx — 9 (47.3) 28 (54.9)
Systemic therapy regimen [no. (%)]
Adjuvant therapy 9 (47.4) 19 (100.0) 24 (47.0)
Neoadjuvant therapy 0 (0.0) 0 (0.0) 0 (0.0)
Overall survival: median follow-up
time (range) [months]
48 (8–194) 23 (8–45) 20 (1–119)
No. of reported deaths (%) 12 (63.2) 3 (15.8) 26 (50.9)
Local relapse of HNSCC
[no. (%)]
— — 8 (15.7)
Time HNSCC until lung tumour:
Median (range) [months]
— — 17 (0–139)
Staging UICC (7th edition)
Stage I [no. (%)] 10 (52.6) 0 (0.0) 22 (43.1)
Stage II [no. (%)] 3 (15.8) 2 (10.5) 5 (9.8)
Stage III [no. (%)] 6 (31.6) 7 (36.8) 17 (33.3)
Stage IV [no. (%)] 0 (0.0) 10 (52.6) 0 (0.0)
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patients (Fig 4G, right, log-rank P = 0.0188, hazard ratio = 0.3748,
95% CI: 0.1155–1.216). Notably, one lung tumour was HPV16-
positive and was identified both clinically and by proteomic clas-
sification as metHNSCC. Furthermore, when we excluded all
cases that were related to the training cohort, we observed a
similar prognostic separation using the proteomic classifier only
(Fig 4H).
In summary, our proteomic analysis revealed a robust multi-
parametric diagnostic signature consisting of more than 1,000
proteins for differentiation between primary SQCLC and
metHNSCC.
Discussion
Patients with squamous cell carcinomas of the head and neck can
develop metachronous lung metastases (metHNSCC), but also inde-
pendent primary squamous cell lung cancers (SQCLC). Differentia-
tion between these two conditions is of fundamental clinical
importance for therapeutic stratification. However, owing to the
large number of morphological and genomic features that are shared
by these tumour entities, diagnostic biomarkers are lacking so far
and the clinical criteria currently used for differentiation between
these tumour types are poorly validated and unreliable (Ichinose
et al, 2016b).
Earlier studies that analysed loss of heterozygosity, p53 mutation
status, gene expression, copy number alterations or protein expres-
sion by immunohistochemistry (Geurts et al, 2005, 2009; Talbot
et al, 2005; Ichinose et al, 2016a; Campbell et al, 2018) likewise
failed to distinguish reliably between metHNSCC and SQCLC. There-
fore, we here used a Super-SILAC-based quantitative mass spec-
trometry approach, to compare the protein expression profiles of
formalin-fixed and paraffin-embedded (FFPE) SQCLC and HNSCC
tissues, with the aim of establishing a diagnostic biomarker signa-
ture. In smaller patient cohorts of less than 45 patients, a similar
approach has been successfully used to reveal proteomic diagnostic
signatures that distinguish between breast cancer and lymphoma
subtypes (Deeb et al, 2015; Tyanova et al, 2016).
Our comparative proteomic approach revealed 518 proteins with
significantly different expression levels in HNSCC and SQCLC. We
were able to validate the differential expression of selected proteins
including CK19, FAM83H, HMGCS-1, LGALS7 and FTL by immuno-
histochemistry, demonstrating the discovery potential of the mass
spectrometry-based approach. Interestingly, HMGCS-1 and FAM83H
have previously been described as oncogenic factors. FAM83H
expression was shown to be up-regulated in lung-, breast-, liver-
and many more cancer types, and its expression was correlated with
a poor prognosis in head-and-neck cancer (Snijders et al, 2017;
Zhao et al, 2017). HMGCS-1 activity was shown to be important for
oncogenic survival-promoting signalling by mutant B-Raf, highlight-
ing the direct involvement of HMGCS-1 in oncogenic signalling
pathways (Snijders et al, 2017; Zhao et al, 2017). Interestingly,
intersection of our proteomic data with functional genomic data
revealed that some of the differentially expressed marker proteins
were genetic dependencies in either of the two tumour types.
Furthermore, gene-set-enrichment analysis of the 518 differentially
expressed proteins revealed RNA-processing including splicing as
one of the pathways showing the greatest difference in regulation
between SQCLC and HNSCC. In this context, we note that altered
phosphoproteomic profiles affecting splicing factors have previously
been shown to be functionally relevant for the survival of HNSCC
cancer cell lines (Radhakrishnan et al, 2016).
Despite these marked and reproducible differences, the distinc-
tion between SQCLC and metHNSCC is not trivial. Our data show
that a distinction with clinically actionable accuracy requires a diag-
nostic signature rather than single markers. By training a linear
support vector machine to discriminate between SQCLC and
HNSCC, we achieved a diagnostic bootstrapped accuracy of 90.5%
on the training data and 86.8% in an independent validation cohort.
The minimum number of features required to achieve this accuracy
was 1,100 proteins. Importantly, in contrast to all established clini-
cal criteria used for this purpose, our proteomic signature was able
to stratify patients with lung tumours of doubtful origin into risk
groups with significantly different prognosis. In detail, patients with
tumours that our signature had classified as “probably metastatic
HNSCC” had a poorer outcome than patients with tumours that had
been classified as “probably primary SQCLC”; this is in good accor-
dance with the predicted clinical course of the two conditions.
This finding underscores the assertion that a reliable distinction
between such closely related tumour types is possible if multipara-
metric protein expression signatures are used. Similar observations
have previously been made for other closely related tumour types,
for instance diffuse large B-cell lymphomas, which can be differenti-
ated as either activated B-cell-like or germinal centre B-cell-like
lymphomas only by complex gene expression signatures, while less
complex diagnostic markers appear to be unreliable (Alizadeh et al,
2000; Rosenwald et al, 2002; Benesova et al, 2013).
In summary, our study shows that standardised quantitative
mass spectrometry-based proteomic analysis on FFPE tissues is a
very promising and powerful tool for advanced tumour diagnostics
and adds new information beyond nucleic acid-based methods.
Importantly, once established, the complete workflow from a FFPE
tumour sample down to the analysis can be performed within one
week, which is comparable to the time required for next-genera-
tion sequencing workflows in pathology laboratories. The imple-
mentation of a protein quantification standard allows long-term
comparability between individual samples, as well as between
mass spectrometry platforms, with the perspective to leverage the
enormous information embedded in FFPE tumour archives world-
wide.
Materials and Methods
Tissue samples
Tissue samples were obtained from surgical resections at the
Department of Thoracic Surgery and the Department of Otorhino-
laryngology of the University Medical Centers Go¨ttingen and
Frankfurt a.M. None of the patients had received neoadjuvant
chemotherapy. Approval for using the human patient material in
this study was obtained from the Ethics Committee of the University
Medical Center Go¨ttingen (#1-2-08,9-12-10) and Frankfurt a.M.
(#SKH-01-2016). Informed consent was obtained from all patients.
All procedures were conducted in accordance with the Declaration
of Helsinki and institutional, state and federal guidelines.
10 of 15 EMBO Molecular Medicine 10: e8428 | 2018 ª 2018 The Authors
EMBO Molecular Medicine Proteomic map of squamous cell carcinomas Hanibal Bohnenberger et al
Immunohistochemistry
Immunohistochemical reactions were performed as described previ-
ously (Mohr et al, 2017). Briefly, 2-lm tissue sections were incu-
bated in EnVision Flex Target Retrieval Solution, pH high or low
(Dako) followed by incubation of primary antibodies against CK5/6
(Dako, prediluted, high), CK7 (Dako, prediluted, high), p63 (Bio-
Genex, prediluted, high), TTF-1 (Dako, prediluted, high), CD34
(Dako, prediluted, low), CK19 (Dako, prediluted, high), FTL (Atlas
antibodies, 1:1,000, high), FAM83H (1:500, low), LGALS7 (Abcam,
1:20,000, high) or HMGCS1 (Atlas antibodies, 1:200, low) at room
temperature for 20 min. Polymeric secondary antibodies coupled to
HRPO peroxidase (EnVision Flex+, Dako) and DAB (Dako) were
applied to visualise the sites of immunoprecipitations. Tissue
samples were analysed by light microscopy after counterstaining
with Meyer’s haematoxylin. Microvessel density was evaluated by
staining of CD34 and counting of microvessels in five 10-fold magni-
fication pictures. Tissue samples for immunohistochemical staining
of CK19, FTL, FAM83H, LGALS7 and HMGCS1 were assembled in
tissue microarrays prior to immunostaining, and all tissue samples
were evaluated considering staining using a four-stage staining
score multiplied with the percentage of positive stained tumour
cells. The intensity of staining was evaluated on a graded scale
(0 = negative; 1 = weakly positive; 2 = intermediately positive;
3 = strongly positive).
TCGA data analysis
Mutational profile data for a cohort of 178 lung squamous carci-
noma patients (LUSC, run date 20160128) and 279 head-and-neck
squamous cell carcinoma patients (HNSC, run date 20160128) from
The Cancer Genome Atlas (TCGA) were retrieved using R version
3.4.3 and the Bioconductor package RTCGAToolbox, version 2.6.0
(Samur, 2014). Mutation rates were computed with the getMuta-
tionRate function in RTCGAToolbox.
HPV analysis
Head-and-neck squamous cell carcinoma samples were tested for 16
HPV types (HPV 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
66 and 68) using multiplex-based fluorescence PCR (F-HPV typingTM,
Genomed Diagnostics AG, Altendorf, Switzerland) and a subsequent
fragment analysis using the ABI 3500 Genetic Analyzer (Life Tech-
nologies, Carlsbad, CA, USA). The data were analysed with the
GeneMapper 5 Software (Life Technologies, CA, USA).
Targeted next-generation sequencing
Targeted next-generation sequencing (NGS) was performed for
genetic characterisation of all tumour samples. First, tumour areas
were identified by a pathologist, and DNA was extracted from these
areas by macrodissection followed by proteinase K treatment and
automated extraction using the Maxwell 16 Research System
(Promega, Madison, USA) or the InnuPureC16 System (Analytik-
jena, Jena, Germany) following the manufacturers’ protocols. The
DNA content was measured using a real-time qPCR-based method.
The custom-made lung cancer panel consisted of 205 amplicons
for the detection of mutations in 17 lung cancer-related genes
including ARAF exon 7; BRAF exons 11, 15; CTNNB1 exon 3; DDR2
exons 3–18; EGFR exons 18–21; FGFR2 exons 8, 9, 10, 12, 17, 20;
FGFR3 exons 7, 10, 15; HER2 exon 19, 20; KEAP1 exons 2–6; KRAS
exons 2–4; MAP2K1 exon 2; MET exon 14, 16–19 and intron 14, 15;
NFE2L2 exon 2; NRAS exons 2–4; PIK3CA exons 9, 20; PTEN exons
1–8, and TP53 exons 5–8. Isolated DNA (10 ng each) was amplified
with four customised GeneRead Primer Pools (Qiagen). PCR prod-
ucts from the same patient were pooled after treatment with FuPa
reagent. Following purification with Agencourt AMPure XP (Beck-
man Coulter, Brea, CA, USA), PCR products were incubated with
NEXTflexTM DNA Adenylation Mix (Bioo Scientific Corp., Austin,
TX, USA). NEXTflexTM DNA Barcodes were used as adapters (Bioo
Scientific Corp.). After the bead size selection, NEXTflexTM PCR
Master Mix (Bioo Scientific Corp.) was used for the final PCR
amplification. Library products were quantified with a Qubit 2.0
Fluorometer (Qubit ds DNA HS Kit, Life TechnologiesTM), diluted
and pooled in equal amounts. 6–8 pM were spiked with 5% PhiX
DNA (Illumina, San Diego, CA, USA) and sequenced with the
MiSeqTM reagent Kit V2 (300-cycles, Illumina). Data were exported
as FASTQ files. FASTQ files were aligned against reference NCBI
build 37 (hg19) and annotated with a modified version of software
previously described (Peifer et al, 2012). Resulting BAM files were
visualised using the Integrative Genomics Viewer (IGV, Cambridge,
USA). Called variants were then imported into a FileMaker (File-
Maker GmbH, Germany) database for further analysis, annotation
and reporting. A 5% cut-off for variant calls was used, and results
were only interpreted if the coverage was >200×.
Sample preparation for proteomic analysis
Tumour areas containing at least 80% tumour cells were marked by
a pathologist on an H&E-stained slide, and corresponding areas of
five sequential unstained 10 lm thick slides were isolated by
macrodissection. Tumour samples were deparaffinised by incuba-
tions in xylene and absolute ethanol, each twice for 5 min at room
temperature. Afterwards, samples were vacuum-dried and resus-
pended in lysis buffer containing 100 mM ABC, pH 8.0, 4% SDS,
0.2% DCA and 50 mM TCEP. Samples were incubated for 60 min at
90°C, sonicated for 3 min and centrifuged for 15 min at 20,000 g at
room temperature.
The Super-SILAC mix was composed of the cell lines NCI-H2228,
HCC15, HCC44 and NCI-H1339. All cell lines were purchased from
American Type Culture Collection (ATCC) and were metabolically
labelled for more than 10 cell cycles with 13C6-arginine (Arg + 6)
and D4-Lysine (Lys + 4) (Cambridge Isotope Laboratories) by cultur-
ing them in RPMI medium in which lysine and arginine were
replaced by Arg + 6 and Lys + 4 and supplemented with 10% dial-
ysed serum and antibiotics. For cell lysis, cells were washed with
PBS and lysed with the same lysis buffer as described above.
Lysates were incubated at 90°C for 15 min and then sonicated for
3 min.
Protein concentrations of the lysates were determined using the
660 nm and IDCR Kit (Thermo Fisher) following the manufac-
turer’s instructions. Equal protein amounts of each clarified tissue
lysate and Super-SILAC quantification standard were mixed for
further filter-aided sample preparation (FASP) as described before
(Wisniewski et al, 2009; Erde et al, 2014; Bohnenberger et al,
2015). Briefly, the mix of tissue lysate and quantification standard
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was combined with 200 ll of 8 M urea and 0.2% deoxycholic acid
(DCA) in 100 mM ABC, pH 8.0 and loaded onto a 30-kDa micron
filter (Millipore). Subsequently, the filter was washed four times
with the same buffer for 10 min at 14,000 g at room temperature
to rid the sample of SDS. Subsequently, protein samples were
alkylated with 50 mM IAA in 100 mM ABC, pH 8.0, for 60 min,
and urea was washed out three times with 0.2% DCA in 50 mM
ammonium bicarbonate (ABC), pH 8.0, by centrifugation for
10 min at 14,000 g at room temperature. Samples were digested
overnight at 37°C with 1 lg of sequencing-grade trypsin
(Promega), and peptides were collected by resuspending with
50 mM ABC, pH 8.0.
To remove deoxycholic acid and Tween-20 from the sample, the
resulting peptide-containing solution was mixed with 200 ll ethyl
acetate and 2.5 ll TFA. Thereafter, 200 ll ethyl acetate was added,
samples were sonicated for 10 s and then centrifuged at 16,000 g for
10 min at room temperature, and finally, the upper organic layer
was removed. Samples were vacuum-dried and washed three times
with 50% methanol. Afterwards, the peptides were desalted with
ZipTips (Merck Millipore) or fractionated with PierceTM High pH
Reversed-Phase Peptide Fractionation Kit (Thermo Scientific)
according to the manufacturer’s instructions, and finally, resulting
peptides were again vacuum-dried.
Mass Spectrometry
The peptides were resuspended in sample loading buffer (2%
acetonitrile and 0.05% trifluoroacetic acid) and were separated
by an UltiMate 3000 RSLCnano HPLC system (Thermo Fisher
Scientific) coupled online to either an Orbitrap Fusion or a Q
Exactive HF. First, the peptides were desalted on a reverse-phase
C18 pre-column (Dionex 5 mm long, 0.3 mm inner diameter) for
3 min. After 3 min, the pre-column was switched online with the
analytical column (30 cm long, 75 lm inner diameter) packed in-
house with ReproSil-Pur C18 AQ 1.9 lm reversed-phase resin
(Dr. Maisch GmbH). Solvent A consisted of 0.1% formic acid in
water, and solvent B consisted of 80% acetonitrile and 0.1%
formic acid in water. The peptides were eluted from buffer B (5–
42% gradient) at a flow rate of 300 nl/min over 166 min. The
temperature of the pre-column and the column was set to 50°C
during the chromatography. MS data were acquired on an Orbi-
trap Fusion in data-dependent Top speed mode, where numerous
precursors within the m/z range of 350–1,500 Th and charge
state of 2–6 were selected from a survey MS1 scan for MS2 frag-
mentation with an isolation window of 1.6 Th and a maximum
cycle time of 3 s. MS1 scans were acquired at a resolution of
120,000 and AGC target of 4E5. Selected precursors underwent
HCD fragmentation with a normalised collision energy (NCE) of
35. MS2 scans were acquired in the ion trap in rapid-scan mode
with maximum ion injection (IT) time of 250 ms and AGC target
of 3E3. All scan events were automatically parallelised. Dynamic
exclusion (DE) was set to 60 s. For the measurement on the Q
Exactive HF, the mass spectrometer was operated in Top 30
data-dependent mode, where the most intense 30 precursors
within the m/z range of 350–1,500 were selected for MS2 frag-
mentation with an NCE of 28. MS2 spectra were acquired in the
Orbitrap with a resolution of 15,000 and maximum IT of 60 ms.
AGC for MS1 and MS2 scans were 1E6 and 1E5, respectively. DE
was 45 s. Other settings were the same as the ones on the Orbi-
trap Fusion.
MS data processing
MS/MS spectra were searched against a UniProtKB/Swiss-Prot
human database containing 134,921 protein entries (downloaded in
July 2014) supplemented with 245 frequently observed contaminants
collated with the Andromeda search engine (Cox et al, 2011). Precur-
sor and fragment-ion mass tolerances were set to 6 and 20 ppm,
respectively, after initial recalibration. Protein N-terminal acetylation
and methionine oxidation were allowed as variable modifications.
Cysteine carbamidomethylation was defined as a fixed modification.
Minimum peptide length was set to seven amino acids, with a maxi-
mum of two missed cleavages. The false discovery rate (FDR) was
set to 1% at both the peptide and the protein level using a forward-
and-reverse concatenated decoy database approach.
For SILAC quantification, multiplicity was set to two for double
SILAC (Lys + 0/Arg + 0, Lys + 8/Arg + 10) labelling. At least two
ratio counts were required for peptide quantification. The “match
between runs” option of MaxQuant was disabled, and the “re-quan-
tify” option was enabled.
Intersection of proteomic and CRISPR/Cas9 loss-of-function
screen data
In order to identify whether the 518 differentially expressed proteins
in HNSCC and SQCLC showed evidence of functional dependency in
these tumour types, we interrogated publicly available data
The paper explained
Problem
Head-and-neck squamous cell carcinoma (HNSCC) is a frequently
occurring disease, and long-term survival of patients with resectable
HNSCC is often limited by lung metastasis. Because tobacco-smoking
is a main risk factor for the development of HNSCC, HNSCC patients
are also at high risk of developing lung cancer. In the context of
HNSCC, differentiation between lung metastasis and secondary squa-
mous cell lung cancer has important prognostic and therapeutic
implications. However, reliable biomarkers for differentiation between
these tumour types are lacking because of their shared morphologies
and genomic features.
Results
Mass spectrometry-based protein expression profiling of HNSCC and
squamous cell lung cancer samples revealed proteomic differences
between the two tumour types. Using supervised machine learning,
we identified a proteomic biomarker signature for differentiation of
HNSCC-derived lung metastasis and primary lung tumours. This
signature was validated in a cohort of lung tumours derived from
patients with prior HNSCC.
Impact
This study demonstrates the feasibility and the added value of quanti-
tative proteomics in advanced tumour diagnostics as it provides (i) a
diagnostic molecular biomarker signature for differentiating between
HNSCC-derived lung metastasis and metachronous squamous cell
lung cancer in patients with prior HNSCC, and (ii) a proteomic
resource for these tumour types.
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(https://depmap.org/portal/dataset/download/Avana/portal-Ava
na-2018-04-11.csv) from a genome-scale CRISPR-Cas9 functional
screen using the Avana 1.0 library in 391 cancer cell lines that
included 12 HNSCC (BHY, BICR22, BICR56, BICR6, CAL27, CAL33,
DETROIT562, FADU, HSC3, PECAPJ34CLONEC12, UPCISCC152,
YD38) and 10 SQCLC (HARA, HCC15, HCC95, KNS62, LK2,
LUDLU1, NCIH2170, NCIH520, RERFLCAI, SKMES1) cell lines
(Doench et al, 2016; Meyers et al, 2017). Not all differentially
expressed proteins identified in our study were included in the
CRISPR-Cas9 screening results, and therefore, this analysis was
limited to those that overlapped (n = 471/518 differentially
expressed proteins, 28/30 HNCSC highly expressed proteins, 73/79
SQCLC highly expressed proteins). We performed a two-class
comparison between genetic dependencies in HNSCC and SQCLC
with a difference of means two-sided t-test and intersected these
data with the proteins that were identified as differentially expressed
between HNSCC and SQCLC.
Statistical data analysis
Data analysis was performed in R version 3.4.1 (R-Core-Team,
2017) and Bioconductor version 3.2 (Huber et al, 2015). Due to the
agnostic approach pursued, no prior sample size computation was
performed; all available samples were included in the analysis.
Proteomic data were processed as follows: Proteins with more than
2/3 missing values were excluded from further analysis. For the
remaining 2,586 proteins, missing values were imputed using k-
nearest-neighbour imputation with k = 10. Univariate analysis using
the empirical Bayes approach was performed with the Bioconductor
package limma (Ritchie et al, 2015), using the lmFit and eBayes
functions. P values were corrected using the false discovery rate.
For tests involving comparisons of means, data were assessed for
normality and similarity of variances between groups, and a t-test
(with correction for unequal variances when appropriate) or a
Wilcoxon test was chosen accordingly. Multivariate analysis was
performed using the R package caret (Kuhn, 2008). Support vector
machine training was performed using bootstrapping with 25 repeti-
tions, with parameter C = 1 in the SVM and a linear kernel. Feature
selection was done using recursive feature elimination. Survival
analysis was performed using the Kaplan–Meier estimator and the
log-rank test. In all analyses, the investigator was blinded for
tumour types in the validation cohort and for patient outcome for
the classification of tumours of unknown origin.
Data availability
All of the raw files and MaxQuant search results have been
deposited in the ProteomeXchange Consortium (http://proteomece
ntral.proteomexchange.org/cgi/GetDataset) via the PRIDE partner
repository (Vizcaino et al, 2014) with the dataset identifier
PXD007705.
Expanded View for this article is available online.
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